Meningococcal disease and vaccination in North America
- PMID: 11885732
- DOI: 10.1046/j.1440-1754.2001.00679.x
Meningococcal disease and vaccination in North America
Abstract
In North America, meningococcal disease occurs at a rate of I case per 100000 population per year, producing 2725 cases notified in the US in 1998 and 155 laboratory confirmed cases in Canada in the same year. A majority of these cases occur in the winter season and in early childhood, with a case fatality rate of approximately 10%. There has been an increase in the proportion of cases due to serogroup Y meningococci over the past decade: in 1995-98 in the US, 33% of cases were due to serogroup B, 28% were due to serogroup C and 34% were due to serogroup Y; in Canada in 1995-96, 47% of cases were due to serogroup B, 40% were due to serogroup C and 10% were due to serogroup Y. Outbreaks due to serogroup C were more common in the 1990s in the US and a number of outbreaks have occurred in Canada due to organisms from the hypervirulent ET-37 complex. College freshmen in the US in dormitories were found to be at an increased risk of disease. In addition, over the past 10 years, an outbreak of serogroup B disease occurred in the Pacific North-west of the US, with a fourfold increased rate of disease in that region. The explanations for these changes in epidemiology are unknown, but probably reflect the appearance of hypervirulent clones of meningococci and/or changing levels of population immunity. Meningococcal serogroup C polysaccharide-protein conjugate vaccines have been introduced recently in the UK, seem efficacious and offer the potential to reduce the burden of disease in the US and Canada too. Because serogroups other than serogroup C are prevalent in North America, a combination polysaccharide-protein vaccine, including C, Y and possibly W135 serogroups, would be attractive for this population. Although not currently an issue in industrialized nations, inclusion of serogroup A conjugates in any future vaccine policy would be an important decision in driving global prevention of meningococcal disease. A meningococcal conjugate vaccine against serogroup C was licensed in Canada in April 2001.
Comment in
-
Meningococcal vaccines: advances but new questions?J Paediatr Child Health. 2001 Oct;37(5):S1-2. doi: 10.1046/j.1440-1754.2001.00733.x. J Paediatr Child Health. 2001. PMID: 11885730 No abstract available.
Similar articles
-
Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.Vaccine. 2015 Jan 1;33(1):268-75. doi: 10.1016/j.vaccine.2013.09.034. Epub 2013 Oct 6. Vaccine. 2015. PMID: 24103896
-
The changing epidemiology of meningococcal disease in North America 1945-2010.Hum Vaccin Immunother. 2013 Jan;9(1):162-71. doi: 10.4161/hv.22302. Epub 2012 Oct 29. Hum Vaccin Immunother. 2013. PMID: 23108355 Free PMC article. Review.
-
Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec.JAMA. 2001 Jan 10;285(2):177-81. doi: 10.1001/jama.285.2.177. JAMA. 2001. PMID: 11176810
-
Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.Vaccine. 2015 Oct 13;33(42):5678-5683. doi: 10.1016/j.vaccine.2015.08.023. Epub 2015 Aug 20. Vaccine. 2015. PMID: 26299749
-
Evolving meningococcal immunization strategies.Expert Rev Vaccines. 2015 Apr;14(4):505-17. doi: 10.1586/14760584.2015.979799. Epub 2014 Dec 10. Expert Rev Vaccines. 2015. PMID: 25494168 Review.
Cited by
-
Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia.Can J Public Health. 2008 Sep-Oct;99(5):380-2. doi: 10.1007/BF03405245. Can J Public Health. 2008. PMID: 19009920 Free PMC article.
-
Bacterial meningitis: the impact of vaccination.CNS Drugs. 2007;21(5):355-66. doi: 10.2165/00023210-200721050-00001. CNS Drugs. 2007. PMID: 17447825 Review.
-
Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.Hum Vaccin. 2010 Nov;6(11):881-7. doi: 10.4161/hv.6.11.12849. Epub 2010 Nov 1. Hum Vaccin. 2010. PMID: 21339701 Free PMC article.
-
Meningococcal vaccines.Paediatr Drugs. 2004;6(4):251-66. doi: 10.2165/00148581-200406040-00004. Paediatr Drugs. 2004. PMID: 15339202 Review.
-
Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan.BMC Infect Dis. 2006 Feb 15;6:25. doi: 10.1186/1471-2334-6-25. BMC Infect Dis. 2006. PMID: 16478548 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous